KR970704452A - 앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제(Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases) - Google Patents

앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제(Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases) Download PDF

Info

Publication number
KR970704452A
KR970704452A KR1019970700721A KR19970700721A KR970704452A KR 970704452 A KR970704452 A KR 970704452A KR 1019970700721 A KR1019970700721 A KR 1019970700721A KR 19970700721 A KR19970700721 A KR 19970700721A KR 970704452 A KR970704452 A KR 970704452A
Authority
KR
South Korea
Prior art keywords
oxepin
dimethylaminopropylidene
dihydrodibenz
amount
acetic acid
Prior art date
Application number
KR1019970700721A
Other languages
English (en)
Other versions
KR100202155B1 (ko
Inventor
마이클 야니 존
엠. 로벗슨 스텔라
에이지 하야카와
마사시 나카쿠라
Original Assignee
제임스 에이. 아노
알콘 래보레이토리스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23864859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR970704452(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제임스 에이. 아노, 알콘 래보레이토리스, 인코퍼레이티드 filed Critical 제임스 에이. 아노
Publication of KR970704452A publication Critical patent/KR970704452A/ko
Application granted granted Critical
Publication of KR100202155B1 publication Critical patent/KR100202155B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

본 발명은 활성 성분으로서 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산 또는 그의 약제학적으로 허용되는 염을 함유하는 국소적 안과용 제제에 관한 것이다. 본 발명의 제제는 앨러지성 결막염, 춘계 결막염,춘계 각결막염 침 거대 유두상 결막염과 같은 앨러지성 안질환을 치료하느데 유용하다.

Description

앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제(Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (24)

  1. 치료학적으로 유효한 양의 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산 또는 그의 약제학적으로 허용된 염을 함유하는 조성물을 눈에 국소적으로 투여함을 특징으로 하여 앨러지성 안질환을 치료하는 방법.
  2. 제1항에 있어서, 조성물이 용액이며, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001w/v% 내지 약 5w/v%인 방법.
  3. 제2항에 있어서, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약 0.2w/v%인 방법.
  4. 제3항에 있어서, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.1 w/v%인 방법.
  5. 제1항에 있어서, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산이 (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산을 실질적으로 함유하지 않는 (Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산인 방법.
  6. 제5항에 있어서, (Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약5w/v%인 방법.
  7. 제6항에 있어서, (Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약 0.2w/v%인 방법.
  8. 제7항에 있어서, (Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.1 w/v%인 방법.
  9. 제1항에 있어서, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산이(Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산을 실질적으로 함유하지 않는 (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산인 방법.
  10. 제9항에 있어서, (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약 5w/v%인 방법.
  11. 제10항에 있어서, (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약 0.2w/v%인 방법.
  12. 제11항에 있어서, (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.1 w/v%인 방법.
  13. 치료학적으로 유효한 양의 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산 또는 그의 약제학적으로 허용된 염을 함유하는, 앨러지성 안질환을 치료하기 위한 국소적으로 투여할 수 있는 안과용 조성물.
  14. 제13항에 있어서, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약5w/v%인 방법.
  15. 제14항에 있어서, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.001 w/v% 내지 약 0.2w/v%인 방법.
  16. 제15항에 있어서, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.1 w/v%인 방법.
  17. 제13항에 있어서, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산이 (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산을 실질적으로 함유하지 않는 (Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산인 조성물.
  18. 제17항에 있어서, (Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약 5w/v%인 방법.
  19. 제18항에 있어서, (Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약 0.2w/v%인 방법.
  20. 제19항에 있어서, (Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.1 w/v%인 방법.
  21. 제13항에 있어서, 11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산이 (Z)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산을 실질적으로 함유하지 않는 (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산인 조성물.
  22. 제21항에 있어서, (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약 5w/v%인 조성물.
  23. 제22항에 있어서, (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.0001 w/v% 내지 약 0.2w/v%인 조성물.
  24. 제23항에 있어서, (E)-11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[b,e]옥세핀-2-아세트산의 양이 약 0.1 w/v%인 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700721A 1995-06-06 1996-05-03 앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제 KR100202155B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/469,729 1995-06-06
US08/469,729 US5641805A (en) 1995-06-06 1995-06-06 Topical ophthalmic formulations for treating allergic eye diseases
US8/469,729 1995-06-06
PCT/US1996/006289 WO1996039147A2 (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases

Publications (2)

Publication Number Publication Date
KR970704452A true KR970704452A (ko) 1997-09-06
KR100202155B1 KR100202155B1 (ko) 1999-06-15

Family

ID=23864859

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700721A KR100202155B1 (ko) 1995-06-06 1996-05-03 앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제

Country Status (20)

Country Link
US (1) US5641805A (ko)
EP (1) EP0799044B1 (ko)
JP (1) JP3068858B2 (ko)
KR (1) KR100202155B1 (ko)
CN (1) CN1082367C (ko)
AT (1) ATE220906T1 (ko)
AU (1) AU698854B2 (ko)
CA (1) CA2195094C (ko)
DE (2) DE69622527T2 (ko)
DK (1) DK0799044T3 (ko)
ES (1) ES2179198T3 (ko)
FI (1) FI970489A0 (ko)
LU (1) LU90969I2 (ko)
MX (1) MX9701013A (ko)
MY (1) MY116651A (ko)
NL (1) NL300101I2 (ko)
NO (1) NO311637B1 (ko)
PT (1) PT799044E (ko)
TW (1) TW438588B (ko)
WO (1) WO1996039147A2 (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
PT1037627E (pt) * 1998-07-14 2001-11-30 Alcon Lab Inc Utilizacao do acido 11-(3-dimetilaminopropilideno)-6,11-dihidrodibenz¬b,e|oxepin-2-acetico e seus sais derivados farmaceuticamente aceitaveis para a producao de um medicamento para o tratamento de doencas inflamatorias oftalmicas nao-alergicas e para a prebencao da neovascularizacao ocular
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
CA2374002A1 (en) 1999-06-18 2000-12-28 Alcon Laboratories, Inc. Topical ophthalmic mast cell stabilizers for treating allergic eye diseases
DE60109742T2 (de) 2000-01-25 2005-08-18 Alcon Inc. Antiallergische ophthalmische zubereitungen, geeignet zur anwendung mit kontaktlinsen
EP1284722B1 (en) 2000-05-19 2005-08-24 Alcon Inc. Compositions containing a benzamide disulfide derivative for treating allergic diseases
DK1282599T3 (da) 2000-05-19 2006-07-31 Alcon Inc Disulfidderivater, der er egnede til behandling af allergiske sygdomme
JP2003534317A (ja) 2000-05-19 2003-11-18 アルコン，インコーポレイテッド アレルギー性疾患を処置するためのアニリンジスルフィド誘導体
WO2002089615A2 (en) * 2001-05-03 2002-11-14 Novartis Ag Anti-ige antibody to treat ocular allergies
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
ES2258175T3 (es) * 2001-12-05 2006-08-16 Alcon, Inc. Utilizacion de un antagonista de h1 y remixolona como esteroide inofensivo para el tratamiento de la rinitis.
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
CA2569519A1 (en) * 2004-06-28 2006-01-12 Alcon, Inc. Topical formulations for treating allergic diseases
SI1814538T1 (sl) * 2004-11-24 2010-01-29 Alcon Inc Postopek dovajanje nosnega pršila
JP5315051B2 (ja) 2005-07-08 2013-10-16 千寿製薬株式会社 オロパタジンを含む眼科用経皮吸収型製剤
MX2008012657A (es) 2006-03-31 2009-02-19 Vistakon Pharmaceuticals Llc Tratamientos de las alergias oculares.
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
EP2977042B1 (en) 2007-02-07 2020-01-01 Novartis AG Olopatadine formulations for topical nasal administration
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CA2698651A1 (en) * 2007-09-06 2009-03-12 Kyowa Hakko Kirin Co., Ltd. Eye drop containing dibenz [b,e] oxepin derivative
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
IT1397503B1 (it) 2009-04-21 2013-01-16 F S I Fabbrica Italiana Sint Processo per la preparazione di olopatadina
WO2011008923A2 (en) * 2009-07-17 2011-01-20 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
WO2011041640A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
TW201206936A (en) 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
TWI544922B (zh) * 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN103202833A (zh) * 2012-12-25 2013-07-17 常州市亚邦医药研究所有限公司 一种奥洛他定或其盐的药用组合物及其制备方法
US20160271097A1 (en) * 2013-10-31 2016-09-22 Nephron Pharmaceuticals Corporation Formulation of olopatadine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370324A (en) * 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) * 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤

Also Published As

Publication number Publication date
NO970517L (no) 1997-04-03
US5641805A (en) 1997-06-24
WO1996039147A2 (en) 1996-12-12
ES2179198T3 (es) 2003-01-16
NO970517D0 (no) 1997-02-05
CA2195094C (en) 2002-02-26
FI970489A (fi) 1997-02-05
JP3068858B2 (ja) 2000-07-24
JPH09510235A (ja) 1997-10-14
DE69622527T2 (de) 2002-12-05
KR100202155B1 (ko) 1999-06-15
MX9701013A (es) 1997-05-31
NL300101I1 (nl) 2002-12-02
DK0799044T3 (da) 2002-10-14
DE10299034I2 (de) 2005-07-07
CN1161000A (zh) 1997-10-01
CA2195094A1 (en) 1996-12-12
NL300101I2 (nl) 2003-01-06
AU5726196A (en) 1996-12-24
WO1996039147A3 (en) 1997-02-20
FI970489A0 (fi) 1997-02-05
DE10299034I1 (de) 2003-01-23
EP0799044A2 (en) 1997-10-08
LU90969I2 (fr) 2002-12-02
EP0799044B1 (en) 2002-07-24
AU698854B2 (en) 1998-11-12
ATE220906T1 (de) 2002-08-15
DE69622527D1 (de) 2002-08-29
TW438588B (en) 2001-06-07
PT799044E (pt) 2002-11-29
CN1082367C (zh) 2002-04-10
NO311637B1 (no) 2001-12-27
MY116651A (en) 2004-03-31

Similar Documents

Publication Publication Date Title
KR970704452A (ko) 앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제(Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases)
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
KR890003369A (ko) 약제학적 제제
KR930001913A (ko) 안염 치료방법
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
FI935847A (fi) L-DOPA-esterikoostumukset
CA2107669A1 (en) Preparation for treating wounds and hemorrhoides
AU2002361265A1 (en) Pharmaceutical composition for the treatment of psoriasis and other skin diseases
AU6199494A (en) New polypeptide compound and a process for preparation thereof
KR900017590A (ko) 좌창(Acne)치료방법 및 그 약제 조성물
AU5910996A (en) Pyrrole derivatives and medicinal composition
BR0314754A (pt) Agente terapêutico ou profilático para a frequência urinária ou a incontinência urinária ou um seu sal de adição de ácido farmaceuticamente aceitável, método para terapia ou profilaxia para frequência urinária, urgência urinária ou incontinência urinária, uso de um derivado de morfina tendo um grupo heterocìclico contendo nitrogênio ou de um seu sal de adição de ácido farmaceuticamente aceitável, derivado de morfina ou um seu sal de adição de ácido farmaceuticamente aceitável, produto farmacêutico, e, composição farmacêutica
US5489576A (en) Therapeutic agent for hemorrhoidal diseases
KR950005823A (ko) 5-아미노-8-메틸-7-피롤리디닐퀴놀린-3-카르본산유도체
PT630252E (pt) Preparacao farmaceutica baseada em ramnolipido contra doencas dermatologicas
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
JPH06234756A (ja) スカベンジャー活性を有し、かつ過酸化および炎症症状を伴う急性および慢性病状に有用なヒドロキシアミンｎ−アシル誘導体
AU3623299A (en) Benzofuroxan derivatives and their use in treating angina pectoris
MX9805317A (es) Agente para la profilaxis y el tratamiento de complicaciones diabeticas.
US5552436A (en) Process for treating hemangioma
ATE165822T1 (de) Chinolin-4-carbonylguanidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE220065T1 (de) Benzopyranderivate und ihre verwendung zur behandlung von herzkrankheiten
KR920002139A (ko) 뇌혈관 수축 치료제
KR890002118A (ko) 디벤즈[b,e]옥세핀 유도체 및 그것을 유효성분으로 하는 의약

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
J204 Request for invalidation trial [patent]
J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20090910

Effective date: 20110513

J2X1 Appeal (before the patent court)

Free format text: INVALIDATION

J2X1 Appeal (before the patent court)

Free format text: INVALIDATION

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20110611

Effective date: 20111223

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20110516

Effective date: 20111223

J202 Request for trial for correction [limitation]
G170 Re-publication after modification of scope of protection [patent]
J221 Remand (intellectual property tribunal)

Free format text: REMAND (INTELLECTUAL PROPERTY TRIBUNAL) FOR INVALIDATION

J303 Written judgement (supreme court)

Free format text: JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20120117

Effective date: 20140516

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20140528

Effective date: 20140922

J121 Written withdrawal of request for trial
J2X1 Appeal (before the patent court)

Free format text: INVALIDATION

J202 Request for trial for correction [limitation]
FPAY Annual fee payment

Payment date: 20150226

Year of fee payment: 17

J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20141024

Effective date: 20150304

J2X1 Appeal (before the patent court)

Free format text: CORRECTION

J122 Written withdrawal of action (patent court)